Vinblastine sulfate

製品コードS4505 バッチS450503

印刷

化学情報

Chemical Structure Synonyms NSC-49842, Vincaleukoblastine, 29060-LE Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C46H58N4O9.H2SO4
分子量 909.05 CAS No. 143-67-9
Solubility (25°C)* 体外 DMSO 100 mg/mL (110.0 mM)
Water Insoluble
Ethanol Insoluble
体内 （毎回新しく調製した物を用意してください）
Clear solution
5%DMSO Corn oil
1.67mg/ml Taking the 1 mL working solution as an example, add 50 μL of 33.3 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 Vinblastine sulfate inhibits microtubule formation and suppresses nAChR activity with IC50 of 8.9 μM in a cell-free assay, used to treat certain kinds of cancer. Vinblastine sulfate induces autophagy and apoptosis.
in vitro The average terminal half-lives of Vinblastine is 14.3 h. When incubated in freshly isolated rat hepatocytes, VLB penetrates rapidly and intensely into the cells, probably through a passive diffusion mechanism followed by tight cellular binding[3]. Vinblastine inhibits the angiogenic response induced by adrenomedullin and is also positive for mitotic slippage, causing micronuclei in mononucleate cells with cytokinesis block[4]. vinblastine gives significant increase in micronucleated mononucleated cells at concentrations that produced approximately 50% cell death and cytostasis or less as calculated using RPD, RICC and RCC[2].
in vivo Vinblastine is a widely used anticancer drug with undesired side effects [6]. A combination of VBL and RAP at very low doses against human HCC gets a satisfactory antiangiogenic effect in vivo[4]. The clinically relevant dose of vinblastine inhibits palmitoylation of tubulin in vivo in CEM cells (effect on depalmitoylation of tubulin)[5].

プロトコル(参考用のみ)

細胞アッセイ 細胞株 Chinese hamster ovary (CHO) cells
濃度 1% (v/v) (dissolved in DMSO)
反応時間 3h
実験の流れ

Six-well treatment plates are set up that contained 5 × 104 cells/mL in each well, suspended in 3 mL culture medium, and these are treated with vinblastine for 3 h followed by 21 h growth.

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Vinblastine resets tumor-associated macrophages toward M1 phenotype and promotes antitumor immune response [ J Immunother Cancer, 2023, 11(8)e007253] PubMed: 37652576
Vinblastine resets tumor-associated macrophages toward M1 phenotype and promotes antitumor immune response [ J Immunother Cancer, 2023, 10.1136/jitc-2023-007253] PubMed: 37652576
Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer [ Cell Rep, 2023, 42(4):112324] PubMed: 37000626
Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells [ J Neurooncol, 2023, 164(3):617-632] PubMed: 37783879
Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells [ J Neurooncol, 2023, 164(3):617-632] PubMed: 37783879
The FAP α -activated prodrug Z-GP-DAVLBH inhibits the growth and pulmonary metastasis of osteosarcoma cells by suppressing the AXL pathway [ Acta Pharm Sin B, 2022, 12(3):1288-1304] PubMed: 35530139
Quantitative reactive cysteinome profiling reveals a functional link between ferroptosis and proteasome-mediated degradation [ Cell Death Differ, 2022, 10.1038/s41418-022-01050-8] PubMed: 35974250
CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine [ Front Endocrinol -Lausanne), 2022, 13:1106175] PubMed: 36601001
CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine [ Front Endocrinol (Lausanne), 2022, 13:1106175] PubMed: 36601001
Establishment and Characterization of NCC-PMP1-C1: A Novel Patient-Derived Cell Line of Metastatic Pseudomyxoma Peritonei [ J Pers Med, 2022, 12(2)258] PubMed: 35207746

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。